BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements. The research study, titled “Myoelectric Arm Orthosis in Motor Learning-Based Therapy for Chronic Deficits After Stroke and Traumatic Brain Injury,” was funded by the U.S. Army Medical Research Acquisition Activity, and supported by the Office of Secretary of Defense for Health Affairs, through the Orthotics and Prosthetics Outcomes Research Program. It was published in the peer-reviewed journal Frontiers in Neurology, and can be found here.
The study followed thirteen individuals with chronic moderate-to-severe arm weakness from stroke or traumatic brain injury (TBI). Outcomes were collected from in-therapy sessions and home use. The study was conducted by lead investigator and grant recipient Svetlana Pundik, M.D. and colleagues at the Louis Stokes Cleveland Veterans Administration Medical Center.
The authors noted that “Statistically significant and clinically meaningful improvements were observed on Fugl-Meyer (+7.5 points). Gains were seen at week 3, increased further through the in-clinic phase and were maintained during the home phase. Statistically significant changes in Modified Ashworth Scale, Range of Motion, and Chedoke Arm and Hand Activity Inventory were seen early during the in-clinic phase. The Orthotic and Prosthetic User's Survey demonstrated satisfaction with the device throughout study participation. Both stroke and TBI participants responded to the intervention.” The authors concluded, “Use of MyoPro in motor learning-based therapy resulted in clinically significant gains with a relatively short duration of in-person treatment.”
“We are encouraged by the continually increasing body of evidence that demonstrates that the use of MyoPro results in clinically significant gains in a relatively short duration of in-person treatment. We look forward to expanding on these results which may lead to innovations in treatment for patients who suffer from chronic upper extremity weakness,” said Harry Kovelman, M.D., Chief Medical Officer of Myomo. “This data supports why the payer community both in the U.S. and Germany continue to expand its reimbursement coverage for patients. We thank the clinicians and patients involved in this study.”
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.